# Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

Study · id `cardio:ct-nct01229254` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01229254](<https://clinicaltrials.gov/study/NCT01229254>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01229254

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.

## Technical summary

Registry record NCT01229254. Non-randomized; no masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2010-12 (actual). Results posted on 2017-09-18.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 189 participants (enrolled count; ClinicalTrials.gov record NCT01229254, source copy `cardio:ctgov-nct01229254-2023-08-07`, retrieved 2026-10-26)
- Start date: 2010-09 (registry gives no type) (ClinicalTrials.gov record NCT01229254, source copy `cardio:ctgov-nct01229254-2023-08-07`, retrieved 2026-10-26)
- Primary completion: 2010-12 (actual) (ClinicalTrials.gov record NCT01229254, source copy `cardio:ctgov-nct01229254-2023-08-07`, retrieved 2026-10-26)
- Completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01229254, source copy `cardio:ctgov-nct01229254-2023-08-07`, retrieved 2026-10-26)
- Results first posted: 2017-09-18 (ClinicalTrials.gov record NCT01229254, source copy `cardio:ctgov-nct01229254-2023-08-07`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01229254-2023-08-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
- Condition: Atrial Fibrillation
- Condition: Atrial Flutter
- Intervention (Drug): Amiodarone
- Intervention (Drug): Betrixaban 60 mg
- Intervention (Drug): Betrixaban 90 mg
- Intervention (Drug): Betrixaban 30 mg
- Lead sponsor: Portola Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Atrial flutter (`cardio:atrial-flutter`)
- Registry intervention name matches this record: Amiodarone (`cardio:amiodarone`)

## Provenance

Content hash: da3c0356d2c288940c17644914e833a270608bb32250c91b1aaa8d1003756c5b
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
